2018: Briefing note on NIH proposed license to Gilead for CD-30 CAR T technology

Contact: Kim Treanor 202-332-2670; kim.treanor@keionline.org January 5, 2018 The National Institutes of Health (NIH) has proposed an exclusive license with Gilead for certain patent applications for inventions that target CD-30 proteins and CAR T technologies. The proposed license is to… Continue Reading

WHA72: Portuguese Minister of Health, Marta Temido, underscores strong support for the WHO transparency resolution

On Monday, 20 May 2019, the Republic of Korea, Italy, Costa Rica, Greece, Indonesia, Italy, Mexico, Mongolia, Netherlands, Portugal, Republic of Korea, Saudi Arabia, Spain, and Vietnam convened an official side event at the 72nd session of the World Health… Continue Reading

24 May 2019 – KEI panel discussion – Assessing the implications of the development of new cell and gene-based therapies (including CAR T and CRISPR): What role should WHO play?

On Friday, 24 May 2019, Knowledge Ecology International (KEI) will convene an expert panel, “Assessing the implications of developments in cell and gene-based therapies (including CAR T and CRISPR): What role should WHO should play?” from 12h30 to 14h30 in… Continue Reading

Comparison between April 29, May 7, and May 10 versions of WHA 72 resolution on transparency

On Monday, May 13th, Politico published the latest version (May 10, 2019) of the transparency resolution noting the “dizzying number of brackets” in the latest text. The original sponsors are: Italy, Greece, Malaysia, Portugal, Serbia, Slovenia, South Africa, Spain, Turkey,… Continue Reading

WHO donors in 2018 – US, Gates Foundation, UK, GAVI, Germany, OCHA, and Japan: Setting the Agenda for Global Health?

In advance of the 72nd World Health Assembly (20 May 2019 – 28 May 2019), the World Health Organization (WHO) published a document (A72/INF./5, 9 May 2019) entitled, Voluntary contributions by fund and by contributor, 2018. Total voluntary contributions to… Continue Reading

KEI Memo on U.S. Legislation to cap price increases on prescription drugs and to enhance the transparency of R&D costs

On April 30, 2019, KEI issued a memorandum to Congress concerning recent proposed measures to cap drug price increases and to increase the transparency of pharmaceutical research and development costs.  Congress is currently considering several bills that touch on these… Continue Reading